Cancer Vaccine EVX-01 Achieves 80% Immune Response in Melanoma Trial - Stock Titan

Retrieved on: 2025-04-28 13:37:12

Tags for this article:

Click the tags to see associated articles and topics

Cancer Vaccine EVX-01 Achieves 80% Immune Response in Melanoma Trial - Stock Titan. View article details on hiswai:

Excerpt

Evaxion Biotech (NASDAQ: EVAX) has presented compelling new data for its personalized cancer vaccine EVX-01 at the AACR Annual Meeting.

Article found on: www.stocktitan.net